Pasithea Therapeutics CorpNASDAQ:KTTANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.3850/ 10
- Ask / Lots0.4200/ 1
- Open / Previous Close0.0000 / 0.4100
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KTTA |
|---|---|---|
| 09:32 ET | 530 | 0.383 |
| 10:10 ET | 900 | 0.4058 |
| 10:19 ET | 100 | 0.4188 |
| 10:24 ET | 3000 | 0.41 |
| 10:26 ET | 7100 | 0.410101 |
| 10:28 ET | 268 | 0.41 |
| 12:14 ET | 200 | 0.4101 |
| 12:34 ET | 100 | 0.4306 |
| 01:01 ET | 100 | 0.4305 |
| 01:35 ET | 500 | 0.4499 |
| 02:24 ET | 100 | 0.425 |
| 02:26 ET | 2400 | 0.4299 |
| 03:56 ET | 299 | 0.41 |
Mar 2, 2023
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Pasithea Therapeutics Corp | 12.0M | -1.3x | --- |
Curative Biotechnology Inc | 12.0M | -2.0x | --- |
Iterum Therapeutics PLC | 12.0M | -0.3x | --- |
BioRestorative Therapies Inc | 12.1M | -0.3x | --- |
RenovaCare Inc | 12.2M | -2.1x | --- |
Neurobo Pharmaceuticals Inc | 12.7M | 0.0x | --- |
Company Information
Pasithea Therapeutics Corp. is a biotechnology company. The Company is engaged on psychiatric and neurological research regarding central nervous system (CNS) disorders with focus on translating the research into clinic-ready drugs. The Company's secondary operations are focused on establishing anti-depression clinics across the United Kingdom and providing business support services to similar entities in the United States and using psychiatric assessment combined with physician or medical providers to administer intravenous infusions of ketamine.
Contact Information
- Headquarters
- 1111 Lincoln RoadMIAMI BEACH, FL, United States 33139
- Phone
- 786-977-3380
- Fax
- ---
Executives
- Executive Chairman, Co-Founder, Independent Director
- Lawrence Steinman
- Chief Executive Officer, Director
- Tiago Marques
- Chief Financial Officer
- Daniel Schneiderman
- Chief Operating Officer, Director, Head of U.K. Clinics
- Yassine Bendiabdallah
- Independent Director
- Simon Dumesnil
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $12.0M |
|---|---|
Revenue (TTM) | $260.9K |
Shares Outstanding | 29.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.33 |
Book Value | $2.23 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 46.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -4,481.13% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
